Merck & Co. Inc. stock underperforms Thursday when compared to competitors
Shares of Merck & Co. Inc. MRK slid 1.81% to $88.05 Thursday, on what proved to be an all-around mixed trading session for ...
Merck Is Suffering From a Classic Pharma Problem
Blockbuster Keytruda makes up nearly half of Merck’s sales. That’s becoming an issue.
Merck shares plunge as company pauses Gardasil vaccine shipments in China, hurting 2025 outlook
Merck on Tuesday issued full-year 2025 revenue guidance that fell short of Wall Street's expectations. The company said that ...
STAT3d
Merck’s earnings miss focused attention on Gardasil. The real issue is Keytruda
Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...
Why Merck Stock Is Plummeting Today
Merck's stock sank after the company reported fourth-quarter and year-end 2024 earnings this morning. Although it narrowly ...
Analysts Defend Merck Amid Investor Concerns Over Weak Guidance
Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a ...
Merck: Don't Fight The Tape, How Low Can It Go?
Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines. Click for more on MRK Q4 earnings.
The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck
Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.